Search Results

You are looking at 71 - 80 of 449 items for :

  • Refine by Access: All x
Clear All
Full access

Rofieda R. Alwaqfi, Megan I. Samuelson, Natalya N. Guseva, Michelle Ouyang, Aaron D. Bossler, and Deqin Ma

malignant melanoma and carcinomas of breast, lung, gastrointestinal, and urinary tract origin. The tumor cells showed patchy but strong positivity for S100 protein and focal positivity for Melan-A and epithelial membrane antigen (EMA) ( Figure 2D–F ). BRG1

Full access

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

baseline demographic characteristics are shown in supplemental eFigure 1 (available with this article at JNCCN.org ) and Table 1 . Median age was 65.5 years, and most patients were White and male. Genitourinary cancer (47%) and melanoma (23%) were the

Full access

Daniel G. Coit

Full access

Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

cells. Since their development, such as inhibitors of CTLA-4, PD-1, and PD-L1, ICIs have been found to be effective treatment options for various solid tumors, including melanoma; lung, genitourinary, colorectal, and head and neck malignancies; and

Full access

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

restoration of antitumor immunity and cytolysis. Regimens that incorporate ICIs represent the current standard of care in many advanced malignancies, including melanoma, 3 – 5 non–small cell lung cancer (NSCLC), 6 – 8 renal cell carcinoma (RCC), 9 – 11

Full access

Olivia G. Fahey, Elizabeth N. Dow, Jennifer K. Piccolo, and Ticiana A. Leal

educate patients about common ICPi toxicities and ensure appropriate, early recognition and management of irAEs in collaboration with the multidisciplinary team. Methods: Within lung, melanoma, and gastrointestinal medical oncology clinics, a program was

Full access

Suneel D. Kamath, Sheetal M. Kircher, and Al B. Benson III

leukemia, ovarian, and breast. Cancers with the best funding vs deaths were breast, leukemia, and melanoma. Cancers with the best funding vs PYLL were breast, leukemia, and prostate. Colon, liver, lung, and bladder cancers were poorly funded in all 3

Full access

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

diagnoses, followed by melanoma (8%), and Merkel cell carcinoma (<1%). The incidence rate per 100,000 person-years for cSCC was 36 times higher than for the US general adult population. 7 Much of the increased cancer risk associated with organ

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

Overview Basal and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSC), are the most common skin cancers. 1 , 2 More than 1 million cases of NMSC are estimated to be diagnosed each year in the United States and